Immunotherapy in Treating Patients With Metastatic Breast Cancer
Stopped early · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to and kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with metastatic breast cancer who have achieved a partial or complete response after chemotherapy and peripheral stem cell transplantation.
Key facts
- Study ID
- NCT00003432
- Run by
- Duke University
- People needed
- 4
- Starts
- 1998-06-01
- Expected to finish
- 2002-11-01
- Last updated by the study team
- 2013-11-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.